RNA Based Therapeutic Market Expected to Reach $ 25,121.95 million by 2030

According to a new report published by Allied Market Research, titled, “RNA Based Therapeutics Market by Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030,” The global RNA based therapeutics market size generated $4,938.38 million in 2021, and is projected to reach $25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030.

The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology. Moreover, Cancer diagnosis and treatment is currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics, also for the diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized.

RNA based therapeutics is segmented into by type, by application, and by end user. Based on type, the market is segmented into RNA interference (RNAi) technologies and RNA antisense technologies. Based on application, the RNA based therapeutics market is segmented into genetic disorders and auto immune disorders. Based on end user, the market is segmented into research institutes, and hospitals & clinics. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on by type, the market is divided into RNA interference (RNAi) and RNA antisense. RNA antisense segment is projected to show fastest growth during the forecast period, owing to increase in revenue of RNA antisense drug discovery and therapeutics.

Based on application, the market is segmented into genetic disorders and auto immune disorders. genetic disorders segment is projected to show fastest growth during the forecast period, owing to surge in case of genetic diseases, rare disorders, and molecular diagnostics.

Depending on end user, the market is categorized into research institutes, academic institutes, and hospitals & clinics. The research institutes segment is projected to show fastest growth during the forecast period, due to the collaboration of research organizations and academic research institutes or collaborating with government bodies to bear the high cost of research.

This report provides comprehensive competitive analysis and profiles of prominent market players such as Alnylam Pharmaceuticals, Inc., Silence Therapeutics plc, Arbutus Biopharma Corporation, Genzyme (Sanofi), Ionis Pharmaceuticals, Sarepta Therapeutics, Benitec Biopharma Inc, Arrowhead Pharmaceuticals, Biogen, Inc and Gradalis, Inc.

Key Findings of the Study

• By type, the RNA antisense segment held the largest RNA based therapeutics market share in 2020 and RNA interference (RNAi) is expected to have fasted share during the forecast period.
• By application, the genetic disorders segment held the largest market share in 2020 and is expected to remain dominant during the forecast period.
• By end user, the research institute held the largest market share in 2020 and is expected to remain dominant during the forecast period.
• By region, North America is expected to experience market growth at the highest rate, registering a CAGR of 17.5% during the forecast period.